5[3]Camilleri M,Northcatt AR,Kong S,et al.Efficacy and Safety of alosctron in woman with irritable bowel Syndrome:a randomised placebo-controlled[J].Lancet，2000,355(9209)∶1035-1040.
6[1]Talley NJ, Stanghellini V, Heading RC, et al. Functional gastrodoudenal disorders. Gut 1999;45 ( suppl 2 ): Ⅱ 37-42.
7[2]Hirakawa K, Adachi K, Amano K, et al. Prevalence of non-ulcer dyspepsia in the Japanese population. J Gastroenterol Hepatol 1999;14:1083-1087.
8[3]Hyams JS, Davis P, Sylvester FA, et al. Dyspepsia in children and adolescents: a prospective study. J Pediatr Gastroenterol Nutr 2000;30:413-418.
9[4]Adesanya AA, da-Rocha Afodu JT, Elesha, et al. Gastric acid secretion in Helicobacter pylori positive and negative dyspeptic Nigerians. Niger Postgrad Med J 2001;8:61-68.
10[5]Schwartz MP, Samsom M, Van Berge Henegouwen GP, et al. Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.Aliment Pharmacol Ther 2001;15:1921-8.
3Nicholl BI, Halder SL, Macfarlane GJ, et al. Psyehosoeial risk markers for new onset irritable bowel syndrome results of a large prospective population based study[J]. Pain, 2008, 137 (1):147-155.
4O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles [ J ]. Gastroenterology, 2005,128(3) :541-551.
